In untreated EGFR-mutant patients with advanced NSCLC, a combination trial of aumolertinib and anlotinib, an oral multitarget antiangiogenic TKI, showed markedly elevated toxicity, indicating that the combined therapy approach was an unacceptable therapeutic decision in this context [47]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.